Physician profile
John L Bell
NPI 1447343298
$569.72
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $74.76 · 2023: $76.46 · 2024: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $194.04 | 2019-2024 | |
| Boston Scientific Corporation | $70.72 | 2019-2024 | Spaceoar Vue System - 10ml |
| Merck Sharp & Dohme LLC | $62.45 | 2019-2024 | Keytruda, Lynparza |
| Eisai INC. | $27.68 | 2019-2023 | |
| Amgen INC. | $26.01 | 2020 | |
| Genentech USA, INC. | $25.19 | 2019 | |
| Varian Medical Systems, INC. | $24.45 | 2019 | |
| Glaxosmithkline, LLC. | $21.23 | 2023 | Jemperli |
| Alexion Pharmaceuticals, INC. | $21.21 | 2023 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $18.74 | 2020 | |
| Daiichi Sankyo INC. | $18.36 | 2019 | |
| Tactile Systems Technology INC | $16.18 | 2020 | |
| Incyte Corporation | $15.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.17 | 2019 | |
| Allergan, INC. | $13.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.